Malarone (Proguanil Hydrochloride, Atovaquone)

The combination works by targeting two essential parasite pathways. Atovaquone blocks mitochondrial electron transport, halting energy production, while proguanil is converted to cycloguanil, which inhibits dihydrofolate reductase, preventing folate synthesis. Together they produce a synergistic antimalarial effect.

The dosage of Malarone is set by the prescribing clinician based on the indication (prophylaxis or treatment), patient weight, age, renal and hepatic function, and local resistance patterns. Patients should follow the exact regimen provided by their healthcare professional.

Safety data for Malarone in pregnancy are limited, and it is generally recommended only when the potential benefit outweighs the risk. Information on excretion in breast milk is insufficient, so clinicians should assess the risk to the infant before prescribing to nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone offers a favorable safety profile compared with older agents such as chloroquine or mefloquine, especially in areas with high chloroquine resistance. Its dual‑mechanism reduces the chance of resistance development, though cost may be higher than some alternatives.

Malarone tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture. Keep the product out of direct sunlight and away from children.

Malarone is taken orally as a tablet, usually with food or a milky drink to improve absorption. For prophylaxis, it is started 1–2 days before entering a malaria‑risk area, continued daily throughout exposure, and taken for 7 days after leaving the area.

The most serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome, hepatic dysfunction manifested by elevated liver enzymes or hepatitis, and anaphylactic reactions. Patients should seek immediate medical attention if they develop rash, jaundice, or signs of an allergic response.

Malarone is contraindicated in individuals with known hypersensitivity to atovaquone, proguanil or any tablet components. Caution is advised for patients with severe renal or hepatic impairment, and it should be avoided in those with a history of severe allergic reactions to related antimalarial agents.